Want to see SG:42T full AI Analyst Report?
Top Page
Trendlines Group
(SGX:42T)
Select Model
Select Model
Rating:48Neutral
Price Target:
S$0.05
▼(-40.00% Downside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by weak cash generation despite the return to reported profitability and a very high P/E valuation. A low-leverage balance sheet and improved TTM earnings/revenue help offset these risks, but technical signals remain soft with the price below major moving averages and a negative MACD.
Positive Factors
Conservative balance sheet
Low leverage and a sizable equity base reduce financial strain and provide flexibility for portfolio support, investment, and operating needs. This conservative funding position should help Trendlines withstand periods of uneven exits or investment performance without excessive debt-related pressure.
Negative Factors
Negative operating cash flow
Negative operating and free cash flow despite positive reported net income indicates weak cash conversion and raises questions about earnings quality. Continued cash outflows could reduce the resources available for portfolio investment and increase reliance on funding or future monetization events.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and a sizable equity base reduce financial strain and provide flexibility for portfolio support, investment, and operating needs. This conservative funding position should help Trendlines withstand periods of uneven exits or investment performance without excessive debt-related pressure.
Read all positive factors
Trendlines Group (42T) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$78.60M
Dividend YieldN/A
Average Volume (3M)458.45K
Price to Earnings (P/E)6.5
Beta (1Y)0.46
Revenue Growth-31.23%
EPS GrowthN/A
CountrySG
Employees20
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,571,914,300
10 Day Avg. Volume493,930
30 Day Avg. Volume458,450
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)0.85
Price to Sales (P/S)33.32
P/FCF Ratio-11.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Trendlines Group Business Overview & Revenue Model
Company Description
The Trendlines Group Ltd. is a private equity and venture capital firm focused on commercializing innovative technologies. They specialize in early-stage investments, ranging from incubation and seed funding to start-up and even later-stage ventur...
How the Company Makes Money
Trendlines Group generally makes money through a venture-capital/venture-building model tied to its portfolio companies. Key revenue streams typically include: (1) Realized gains from exits: proceeds and profits when portfolio companies are sold, ...
Trendlines Group Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.57M | 1.99M | 1.72M | 4.50M | 3.58M | 2.30M |
| Gross Profit | 7.31M | 343.23K | -1.73M | -793.00K | -3.83M | -5.04M |
| EBITDA | 7.62M | 2.13M | -9.45M | -33.93M | -16.39M | 3.95M |
| Net Income | 7.30M | 1.95M | -9.43M | -33.99M | -14.48M | 6.56M |
Balance Sheet | ||||||
| Total Assets | 91.62M | 85.76M | 75.35M | 78.07M | 107.99M | 121.08M |
| Cash, Cash Equivalents and Short-Term Investments | 5.01M | 4.92M | 5.89M | 6.11M | 6.57M | 18.46M |
| Total Debt | 5.32M | 5.35M | 4.15M | 4.64M | 4.85M | 10.01M |
| Total Liabilities | 6.59M | 8.45M | 7.32M | 9.00M | 12.10M | 18.54M |
| Stockholders Equity | 84.93M | 78.26M | 68.55M | 70.89M | 96.99M | 103.09M |
Cash Flow | ||||||
| Free Cash Flow | -8.57M | -5.89M | -8.86M | -6.42M | -15.04M | 76.00K |
| Operating Cash Flow | -8.56M | -5.87M | -8.84M | -6.34M | -14.93M | 650.00K |
| Investing Cash Flow | -3.98M | -2.38M | -948.00K | 1.92M | 2.05M | -598.00K |
| Financing Cash Flow | 10.70M | 8.09M | 8.64M | 5.97M | 3.13M | 3.60M |
Trendlines Group Technical Analysis
Negative
0.08
Price Trends
0.05
Negative
0.06
Negative
0.06
Negative
Market Momentum
>-0.01
Negative
40.74
Neutral
42.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:42T, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and above the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.74 is Neutral, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:42T.
Trendlines Group Peers Comparison
UnderperformOutperform
Sector (68)
SG:42T
Trendlines Group
0.05
<0.01
9.09%
SG:5RF
Mercurius Capital Investment Limited
0.02
0.00
0.00%
SG:CJN
British and Malayan Holdings Limited
2.50
1.85
284.62%
SG:HKB
AMTD IDEA Group Class A
3.38
-0.22
-6.11%
SG:I49
IFS Capital Ltd.
0.16
>-0.01
-2.44%
Trendlines Group Corporate Events
Trendlines Strengthens Portfolio With U.S. Approvals, Expansion and Final Subscription Installment
Oct 1, 2026
Trendlines completed the second and final installment of a subscription initiated in June 2025, underscoring continued capital structuring for its investment platform. The update highlights active fundraising among its medtech and agrifood portfol...
EcoPhage Wins EPA Nod for Phage-Based GoldenEco Biopesticide in U.S.
Sep 17, 2026
EcoPhage has secured U.S. Environmental Protection Agency approval for GoldenEco, a phage-based biopesticide targeting destructive bacterial diseases in tomatoes and peppers caused by Xanthomonas and Pseudomonas. The product offers growers a targe...
Trendlines Group Completes Final Tranche of S$3.49 Million Share Subscription
Sep 8, 2026
Trendlines Group has completed the second and final installment of a previously announced share subscription, issuing 116,420,795 new ordinary shares for gross proceeds of S$3.49 million. Following the allotment of these Second Installment Subscri...
Trendlines Maintains H1 2026 Profitability as Portfolio Activity Accelerates
Sep 1, 2026
Trendlines Group reported that it remained profitable in the first half of 2026, underscoring steady financial performance and ongoing investor communications through its latest unaudited financials, results release, and August investor presentati...
Trendlines Portfolio Scores U.S. Deals, Patents and EU Project as Fundraising Accelerates
Jul 31, 2026
Trendlines reported a series of portfolio milestones, including ElastiMed securing an exclusive U.S. distribution deal with Nasdaq-listed Tactile Systems Technology Inc. and EcoPhage submitting its fifth product to the U.S. Environmental Protectio...
Trendlines’ ElastiMed Secures Exclusive U.S. Distribution Deal for Wearable Compression Device
Jul 14, 2026
Trendlines’ portfolio company ElastiMed has signed an exclusive U.S. distribution agreement with Nasdaq-listed Tactile Medical for MyoSleeve, its discreet, wearable compression device for lower-leg venous and lymphatic conditions. Tactile Me...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.